What is BRZE's health score?

Braze, Inc. (BRZE) has a TradeApes health score of 54 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BRZE's estimated fair value?

Based on our 5-year discounted cash flow model, Braze, Inc.'s estimated fair value is $14.56 per share, representing a -37.1% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BRZE undervalued or overvalued?

Our model currently rates BRZE as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BRZE... Refresh in a moment for the full analysis.

Braze, Inc. (BRZE)

Technology Overvalued low mixed

$23.14

Updated: 2026-06-04

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

73 Healthy

Relative Value

50 Mixed

Capital Allocation

10 Stressed

Risk

70 Healthy

Est. Fair Value $14.56

DCF Upside -37.1%

Sector Rank #1976 of 7760

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.